Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (²¹¹At).

Abstract

We have developed probes for multiradionuclides radiotheranostics using RGD peptide ([⁶⁷Ga]Ga-DOTA-c[RGDf(4-I)K] ([⁶⁷Ga]1) and Ga-DOTA-[²¹¹At]c[RGDf(4-At)K] ([²¹¹At]2)) for clinical applications. The introduction of an albumin binding moiety (ABM), such as 4-(4-iodophenyl)-butyric acid (IPBA), that has high affinity with the blood albumin and prolongs the circulation half-life can improve the pharmacokinetics of drugs. To perform more effective targeted alpha therapy (TAT), we designed and synthesized Ga-DOTA-K([²¹¹At]APBA)-c(RGDfK) ([²¹¹At]5) with 4-(4-astatophenyl)-butyric acid (APBA), which has an astato group instead of an iodo group in IPBA. We evaluated whether APBA functions as ABM and [²¹¹At]5 is effective for TAT. In addition, we prepared ⁶⁷Ga-labeled RGD peptide without ABM, [⁶⁷Ga]Ga-DOTA-K-c(RGDfK) ([⁶⁷Ga]3), and ¹²⁵I-labeled RGD peptide with ABM, Ga-DOTA-K([¹²⁵I]IPBA)-c(RGDfK) ([¹²⁵I]4), to compare with [²¹¹At]5. Biodistribution experiments of [⁶⁷Ga]3 without ABM, [¹²⁵I]4 and [²¹¹At]5 with ABM were conducted in normal mice and U-87 MG tumor-bearing mice. In addition, two doses of [²¹¹At]5 (370 or 925 kBq) were administered to U-87 MG tumor-bearing mice to confirm the therapeutic effects. The blood retention of [¹²⁵I]4 and [²¹¹At]5 was remarkably increased compared to [⁶⁷Ga]3. Also, [¹²⁵I]4 and [²¹¹At]5 showed similar biodistribution and significantly greater tumor accumulation and retention compared to [⁶⁷Ga]3. In addition, [²¹¹At]5 inhibited tumor growth in a dose-dependent manner. The functionality of APBA as ABM like IPBA, and the usefulness of [²¹¹At]5 as the radionuclide therapy agent for TAT was revealed.